ChemoCentryx Inc $ 57.24 0.03 (0.05%)
Volume:
567,446
Avg Vol (1m):
494,563
Market Cap $:
3.98 Bil
Enterprise Value $:
3.61 Bil
PE Ratio:
0.00
PB Ratio:
10.29
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 6.83 | ||
| Equity-to-Asset | 0.74 | ||
| Debt-to-Equity | 0.17 | ||
| Debt-to-EBITDA | -1.25 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 17.31 | ||
| Beneish M-Score | -1.25 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -85.69 | ||
| Net Margin % | -85.97 | ||
| ROE % | -20.69 | ||
| ROA % | -13.84 | ||
| ROC (Joel Greenblatt) % | -193.13 | ||
| 3-Year Revenue Growth Rate | -16.2 |
CCXI
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 10.29 | ||
| PS Ratio | 60.88 | ||
| EV-to-EBIT | -68.5 | ||
| EV-to-EBITDA | -70.35 | ||
| EV-to-Revenue | 56.08 | ||
| Current Ratio | 8.56 | ||
| Quick Ratio | 8.56 | ||
| Days Sales Outstanding | 0.96 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.4 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 10.28 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 54.51 | ||
| Earnings Yield (Greenblatt) % | -1.47 |